Published in Arch Dermatol on June 01, 2002
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
Gene therapy for cancer: present status and future perspective. Mol Cell Ther (2014) 0.87
Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology (2012) 0.84
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs (2010) 0.83
Melanoma-associated leukoderma - immunology in black and white? Pigment Cell Melanoma Res (2013) 0.82
Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma. J Immunother Cancer (2013) 0.78
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Management of cutaneous melanoma. N Engl J Med (2004) 9.52
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol (2006) 2.87
BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol (2011) 2.87
Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol (2010) 2.83
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol (2011) 2.46
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol (2005) 2.22
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
PTEN signaling pathways in melanoma. Oncogene (2003) 1.98
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol (2005) 1.71
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol (2013) 1.50
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol (2007) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 7-2004. A 48-year-old woman with multiple pigmented lesions and a personal and family history of melanoma. N Engl J Med (2004) 1.38
Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol (2009) 1.37
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Melanoma. J Natl Compr Canc Netw (2009) 1.37
IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest (2013) 1.36
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
Skin cancer prevention and detection practices among siblings of patients with melanoma. J Am Acad Dermatol (2003) 1.22
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20
Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol (2002) 1.19
Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. J Clin Oncol (2013) 1.19
Melanoma in the young: differences and similarities with adult melanoma: a case-matched controlled analysis. Cancer (2007) 1.18
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Central nervous system cancers. J Natl Compr Canc Netw (2011) 1.13
Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res (2009) 1.12
Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn (2003) 1.12
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res (2013) 1.11
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09
The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One (2012) 1.09
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res (2010) 1.08
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol (2002) 1.07
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06
A randomized trial to improve early detection and prevention practices among siblings of melanoma patients. Cancer (2006) 1.05
Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res (2014) 1.05